A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis

BACKGROUND: The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bactericidal activity, safety, and tolerability of a regi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Conde, Marcus B., Mello, Fernanda C. Q., Duarte, Rafael Silva, Cavalcante, Solange C., Rolla, Valeria, Dalcolmo, Margareth, Loredo, Carla, Durovni, Betina, Armstrong, Derek T., Efron, Anne, Barnes, Grace L., Marzinke, Mark A., Savic, Radojka M., Dooley, Kelly E., Cohn, Silvia, Moulton, Lawrence H., Chaisson, Richard E., Dorman, Susan E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861335/
https://ncbi.nlm.nih.gov/pubmed/27159505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0154778
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi